Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 19/2004

01-10-2004 | Guest Commentary

Prulifloxacin

A Viewpoint by Claudio Giberti

Author: Claudio Giberti

Published in: Drugs | Issue 19/2004

Login to get access

Excerpt

Prulifloxacin, the prodrug of ulifloxacin, is a new oral fluoroquinolone that is taken once daily. It is indicated in the treatment of simple cystitis, complicated urinary tract infections (UTIs), and acute exacerbation of chronic bronchitis (AECB). …
Metadata
Title
Prulifloxacin
A Viewpoint by Claudio Giberti
Author
Claudio Giberti
Publication date
01-10-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 19/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464190-00007

Other articles of this Issue 19/2004

Drugs 19/2004 Go to the issue

Guest Commentary

Lumiracoxib

Guest Commentary

Prulifloxacin

Adis Drug Profile

Lumiracoxib

Adis Drug Profile

Anidulafungin

Adis Drug Profile

Anidulafungin

Leading Article

Reactive Oxygen Species in the Cerebral Circulation